Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -24.06% is 26% above its 5-year average of -32.65%, around the middle of its 5-year range (-48.08%–-13.65%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.26% above its 12-month average of -30.17%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -24.06%.
RETURN ON EQUITY (ROE)
-24.06%
RETURN ON EQUITY (ROE) AVG TTM
-30.17%
RETURN ON EQUITY (ROE) AVG 3Y
-32.23%
RETURN ON EQUITY (ROE) AVG 5Y
-32.65%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.26%
CURRENT VS 3Y AVG
+25.37%
CURRENT VS 5Y AVG
+26.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.87%
median of 380 covered companies
CURRENT VS SECTOR MEDIAN
+28.97%
vs the sector median at left
Climb Bio, Inc.
Market Cap
$632.76M
Return on Equity (ROE)
-24.06%
TTM Avg
-30.17%
3Y Avg
-32.23%
5Y Avg
-32.65%
Market Cap
$637.59M
Return on Equity (ROE)
-8.42%
TTM Avg
-4.61%
3Y Avg
-3.17%
5Y Avg
11.46%
Market Cap
$642.31M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$643.37M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$596.36M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$675.41M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$579.88M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$688.14M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
Market Cap
$573.38M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $632.76M | -24.06% | -30.17% | -32.23% | -32.65% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -8.42% | -4.61% | -3.17% | 11.46% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -21.51% | -20.05% | -35.91% | -26.18% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -41.56% | -67.38% | -49.66% | -56.07% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -60.79% | -73.94% | -62.04% | -71.62% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -43.95% | -29.61% | -34.61% | -30.48% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | N/A | 44.05% | 44.05% | 44.05% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -108.93% | -72.41% | -64.95% | -55.74% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 161.13% | 93.89% | 96.07% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 40.62% | 9.52% | -25.24% | -32.61% |
ROE
-24.1%
ROA
-23.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -24.06% |
| 2026-03-31 | -35.65% |
| 2025-12-31 | -37.30% |
| 2025-09-30 | -28.67% |
| 2025-06-30 | -25.17% |
| 2025-03-31 | -48.08% |
| 2024-12-31 | -34.88% |
| 2024-09-30 | -31.59% |
| 2024-06-30 | -28.88% |
| 2024-03-31 | -13.65% |
| 2023-12-31 | -32.64% |
| 2023-09-30 | -35.76% |
| 2023-06-30 | -39.96% |
| 2023-03-31 | -46.49% |
| 2022-12-31 | -35.15% |
| 2022-09-30 | -35.75% |
| 2022-06-30 | -33.72% |
| 2022-03-31 | -27.13% |
| 2021-12-31 | -28.40% |
| 2021-09-30 | -29.32% |
| 2021-06-30 | -43.61% |
| 2021-03-31 | -75.28% |
| 2020-12-31 | -95.83% |
